Kentucky Medicaid GLP-1 Coverage (2026): Pattern #21 — Nullified-Amendment Exclusion State (SB 65 Veto Override April 14, 2026) + Most Permissive MACE Pathway in Series (BMI ≥ 27) + T2D Exclusion From MACE/MASH/OSA Carve-Outs + KEHP-Medicaid Jurisdiction Inversion

What you need to know (TL;DR)

Kentucky Medicaid does not cover GLP-1 drugs for chronic weight management. The categorical exclusion is anchored in 907 KAR 23:010 Section 5(2)(a) (“A drug if used for anorexia, weight loss, or weight gain”). Wegovy and Zepbound are covered only for specific non-weight-management FDA indications — Wegovy for MACE risk reduction (BMI ≥ 27, no T2D) and MASH (F2–F3 fibrosis, no T2D), and Zepbound for moderate-to-severe OSA (BMI ≥ 30, no diabetes). The most important fact of 2025–2026: the Beshear administration formally proposed deleting the weight-loss exclusion entirely from 907 KAR 23:010 (filed September 9, 2025; public hearing November 24, 2025). Senate Bill 65 (sponsor Sen. Stephen West, R-Paris) nullified that amendment. Governor Beshear vetoed SB 65 on April 6, 2026; the Senate overrode 32–6 and the House overrode 79–19. The bill became law April 14, 2026. DMS is legally prohibited from re-promulgating a substantially-similar amendment until June 1, 2027. This article documents that historical record — not a prediction. Separately, the Kentucky Employees’ Health Plan (KEHP) for state workers retains GLP-1 weight-loss coverage in the 2026 plan year at increased cost-sharing — a jurisdiction inversion opposite to Indiana (Pattern #16).

Pattern #21 in the 50-state series: nullified-amendment exclusion state

Kentucky is the 21st state in this 50-state Medicaid GLP-1 coverage series, and the first in a new structural cluster: nullified-amendment exclusion states — states where a governor’s administration formally proposed regulatory adoption of GLP-1 chronic-weight-management coverage and was extinguished by legislative veto override.

Both Tennessee and Kentucky used the identical procedural instrument: an executive-branch administrative regulation filed through formal notice-and-comment rulemaking. Both were reviewed by the same type of legislative body: an Administrative Regulation Review Subcommittee with authority to find amendments “deficient” under state APA law. Tennessee’s General Assembly chose not to nullify the TennCare expansion. Kentucky’s General Assembly chose to nullify the DMS expansion. This is the cleanest counter-example in the 21-state series to date.

Kentucky Medicaid is administered by the Department for Medicaid Services (DMS), a department within the Cabinet for Health and Family Services (CHFS), serving approximately 1.6 million Kentuckians. Pharmacy benefits for all five MCOs and the fee-for-service (FFS) population are administered by a single statewide carve-out PBM: MedImpact Healthcare Systems, Inc. (effective January 1, 2024). The five MCOs — Aetna Better Health of Kentucky, Anthem Blue Cross and Blue Shield Medicaid (HealthKeepers), Humana Healthy Horizons in Kentucky, Passport Health Plan by Molina Healthcare, and WellCare/Wellpoint Kentucky — all defer pharmacy benefits to the MedImpact-administered statewide Kentucky Medicaid Single PDL.

The 907 KAR 23:010 amendment timeline: August 2025 to April 2026

The sequence below is a documented historical record derived from verbatim primary sources. It is not a prediction about future policy.

The proposed amendment would have struck the weight-loss exclusion from 907 KAR 23:010 Section 5, re-lettering the remaining exclusions. The DMS necessity statement reads verbatim:

“This amendment will allow reimbursement for prescription weight loss, anorexia, and weight loss drugs. This amendment is necessary to implement reimbursement for weight loss, anorexia, and weight gain drugs as provided by federal law.”

The affected-population figure, verbatim from the DMS regulatory filing:

“As many as 350,000 Medicaid members have an obesity related diagnosis.”

The DMS cost projection, verbatim:

“DMS estimates an actual impact of $1.1 million in state funds. [...] DMS does not anticipate offering GLP-1 medications without prior authorizations, step therapy, and other utilization management review to ensure appropriate use. DMS further anticipates that cost savings from avoided hospitalizations and other medical interventions. [...] DMS continues to estimate a lower persistence rate, as consistent with the experience in other states that cover GLP-1 medicines.”

Senate Bill 65 (2026 RS) — verbatim legislative nullification

Senate Bill 65 was sponsored by Sen. Stephen West (R-Paris, District 27), chair of the Administrative Regulation Review Subcommittee. The bill is titled “AN ACT relating to deficient administrative regulations and declaring an emergency.” The operative nullification language is in Section 1. The verbatim text of Section 1:

“SECTION 1. A NEW SECTION OF KRS CHAPTER 13A IS CREATED TO READ AS FOLLOWS:

(1) The General Assembly finds that the proposed ordinary amendment to 907 KAR 23:010, Outpatient Pharmacy Program, was found deficient pursuant to KRS 13A.030, on or after March 28, 2025, and before April 15, 2026, as evidenced by the records of the Legislative Research Commission.

(2) Contrary provisions of any section of the Kentucky Revised Statutes notwithstanding:
   (a) If the proposed ordinary amendment referenced in subsection (1) of this section has not been adopted on or before the effective date of this Act, the proposed ordinary amendment shall expire as of the effective date of this Act; or
   (b) If the proposed ordinary amendment referenced in subsection (1) of this section has been adopted on or before the effective date of this Act, the administrative regulation, including any subsequently filed amendments, shall be null, void, and unenforceable as of the effective date of this Act.

(3) Contrary provisions of any section of the Kentucky Revised Statutes notwithstanding, the administrative body shall be prohibited from promulgating an administrative regulation that is identical to, or substantially the same as, the proposed amendment referenced in subsection (1) of this section for a period beginning on January 6, 2026, and concluding on June 1, 2027.

(4) The proposed amendment referenced in subsection (1) of this section shall be available to the public, in the office of the Legislative Research Commission’s regulations compiler.”

The emergency declaration in Section 4:

“Whereas it is crucial that the Commonwealth’s regulatory policy reflect the statutory intent of the General Assembly, an emergency is declared to exist, and this Act takes effect upon its passage and approval by the Governor or upon its otherwise becoming a law.”

The emergency clause accelerated the effective date to April 14, 2026 (the date of the veto override), rather than the standard 90-days-after-adjournment date applicable to most Kentucky bills. The Kentucky Constitution (Article III, § 88) requires only a simple majority of each chamber for a veto override — not a supermajority. The 32–6 Senate vote and 79–19 House vote both cleared that threshold by wide margins. The General Assembly’s Republican supermajority structurally facilitated the override.

Sen. West’s public rationale, verbatim from Kentucky Health News (March 16, 2026):

“The administration wanted to expand Medicaid coverage for GLP-1s. Doctors were already allowed to prescribe GLP-1s, but this expanded it further. We felt it could have been a huge cost and a huge policy discussion.”

The Obesity Action Coalition’s position, verbatim from the same reporting:

“A statement late last year from the Obesity Action Center called on the Kentucky legislature to remove the Medicaid ban on obesity medications to give health care providers a tool to manage this chronic condition that affects more than 34% of adults in the state, costing the state an estimated $36 billion annually.”

The CDC 2024 BRFSS figure, verbatim from the same article:

“The latest Centers for Disease Control and Prevention obesity data shows that 37.2% of Kentucky adults are considered obese, according to the 2024 Behavioral Risk Factor Surveillance System survey.”

DMS is legally prohibited from re-promulgating a substantially-similar amendment until June 1, 2027. This article does not predict whether DMS will re-attempt promulgation after that date. The statutory record stops at SB 65’s June 1, 2027 prohibition window.

The Tennessee counter-example: same procedure, opposite outcome

Tennessee (Pattern #13 in this series) is the structural mirror-image of Kentucky. Both states:

• Used the identical procedural instrument: an executive-branch administrative regulation filed through formal notice-and-comment rulemaking within their respective state APA frameworks.
• Had their proposed regulations reviewed by a legislative Administrative Regulation Review Subcommittee with authority to find amendments “deficient” under state APA law.
• Filed their proposals in the same calendar year (2025), with public hearings in the fall of 2025.
• Used GLP-1s for chronic weight management as the target indication.

The critical distinction is not pharmacological or fiscal — the DMS $1.1 million state-fund projection is far lower than TennCare’s $2.7 million annual fiscal exposure cited in the Tennessee rulemaking fiscal note. The distinction is entirely legislative-political: Tennessee’s Republican-majority General Assembly chose to allow TennCare’s obesity-coverage expansion to stand; Kentucky’s Republican supermajority chose to extinguish DMS’s expansion through SB 65. The contrast between TN and KY is the single most-citable case study in the 21-state series of how state legislatures react differently to formally-identical administrative action on GLP-1 obesity coverage.

Most permissive Wegovy MACE pathway in the series: BMI ≥ 27

Despite Kentucky’s categorical exclusion of GLP-1s for weight loss, its Wegovy MACE pathway is the least restrictive MACE pathway verified in the 21-state series at the BMI threshold. New York (Pattern #3) gates its Wegovy MACE pathway on BMI ≥ 40 — a threshold 13 points above the FDA SELECT trial label minimum. Kentucky uses BMI ≥ 27, matching the FDA SELECT label exactly.

The verbatim initial approval criteria for the Wegovy MACE pathway from the MedImpact Kentucky Medicaid PA Criteria document (effective January 3, 2026):

“1. INITIAL APPROVAL CRITERIA

For Major Adverse Cardiovascular Events (MACE) risk reduction:
  • Patient age ≥ 45 years; AND
  • Being prescribed for MACE risk reduction (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke); AND
  • Prescriber includes documentation (e.g., progress note) within the past year of pre-existing cardiovascular (CV) disease as defined by ≥ 1 of the following:
    o Previous myocardial infarction (MI); OR
    o Previous stroke (ischemic or hemorrhagic); OR
    o Symptomatic peripheral arterial disease: • Amputation due to atherosclerotic disease; • History of peripheral arterial revascularization procedure; • Intermittent claudication with ankle-brachial index (ABI) less than 0.85 (at rest); AND
  • [Documentation of optimization on lipid-lowering therapy (moderate to high intensity statin, PCSK9) AND ≥ 1 of: beta-blocker, RAS inhibitor, antiplatelet]; AND
  • Patient has a body-mass index (BMI) of 27 kg/m² or greater; AND
  • Prescriber includes documentation that the medication will be used in combination with a reduced calorie diet and increased physical activity; AND
  • Patient does not have any of the following:
    o A history of type 2 diabetes;
    o Current A1c of 6.5% or higher;
    o New York Heart Association (NYHA) class IV heart failure;
    o End-stage kidney disease or dialysis;
    o Plans to undergo coronary, carotid, or peripheral revascularization;
    o No personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); [pregnancy/lactation contraindications];”

The BMI ≥ 27 threshold makes the KY Wegovy MACE pathway accessible to a broader patient population than the NY pathway. However, eligibility requires established cardiovascular disease (prior MI, stroke, or PAD with ABI < 0.85) plus optimization on lipid-lowering and adjunctive cardiovascular therapy — the pathway is not available for primary prevention.

The T2D exclusion: a unique structural restriction across MACE, MASH, and OSA

All three Kentucky Medicaid carve-out pathways for Wegovy and Zepbound — MACE, MASH, and OSA — explicitly require the patient NOT have type 2 diabetes. This is a unique structural restriction in the 21-state series. Most state carve-out pathways gate access on the positive indication; few impose an affirmative T2D exclusion from the non-weight-loss indications.

The T2D exclusion appears verbatim in all three PA criteria documents:

• Wegovy MACE: “Patient does not have any of the following: A history of type 2 diabetes; Current A1c of 6.5% or higher.”
• Wegovy MASH: “Patient does not have any of the following: A history of type 2 diabetes.”
• Zepbound OSA: “Patient does NOT have any of the following: i. A history of diabetes; ii. Current A1c of 6.5% or higher.”

The policy logic: Kentucky Medicaid already covers GLP-1 receptor agonists for type 2 diabetes as a separate PDL class (Ozempic, Trulicity, Victoza as preferred; Byetta, Mounjaro, Rybelsus as non-preferred). A diabetic patient with cardiovascular disease, MASH, or OSA is routed to the GLP-1 RA T2D class under the diabetes indication — not to the Wegovy MACE, Wegovy MASH, or Zepbound OSA carve-out pathways. The T2D exclusion prevents diabetic patients from double-accessing the same drug class under two separate indication pathways.

For patients: a person with both cardiovascular disease and T2D who qualifies clinically for Wegovy MACE under the FDA SELECT label will NOT be able to access Wegovy through the MACE carve-out in Kentucky Medicaid. Their access point is the T2D PDL class (Ozempic, Trulicity, Victoza for T2D + potential cardiovascular benefit — a separate clinical discussion with their prescriber). A person with T2D plus moderate-to-severe OSA who might clinically qualify for Zepbound under the FDA OSA label will similarly be routed to the T2D GLP-1 RA class, not the OSA pathway.

PDL fragmentation: stand-alone PA criteria documents vs. dedicated drug class

Wegovy and Zepbound are not enumerated in the Kentucky Medicaid PDL drug class table at all. The PDL’s GLP-1 receptor agonists class lists only T2D-indicated agents: Ozempic, Trulicity, Victoza (preferred), Byetta, Mounjaro, Rybelsus, Soliqua, and Xultophy (non-preferred). The MedImpact PDL document itself notes:

“To view the most current PA criteria, please visit our Kentucky Medicaid portal: [kyportal.medimpact.com]”

Coverage for Wegovy (MACE and MASH) and Zepbound (OSA) is administered through separately-posted stand-alone PA criteria documents on the MedImpact Kentucky portal. This creates a fragmented administrative structure compared to states that have created dedicated PDL classes for these indications:

From a prescriber navigation standpoint, the Kentucky structure is more fragmented than Ohio’s or Minnesota’s. A prescriber looking only at the PDL drug class table would not see Wegovy or Zepbound listed at all, and might incorrectly conclude they are categorically excluded. The MACE, MASH, and OSA pathways are accessible only through the MedImpact portal PA criteria documents — a separate lookup workflow.

The GLP-1 RA T2D PA criteria document itself reproduces the categorical exclusion as a footnote, confirming the operational architecture:

“*Drugs used for anorexia, weight loss, or weight gain are excluded from coverage.”

KEHP vs. Kentucky Medicaid: a jurisdiction inversion

The Kentucky Employees’ Health Plan (KEHP) — the state employee plan administered by Anthem (medical) and CVS Caremark (pharmacy) for approximately 270,000 state employees and their dependents — retains GLP-1 weight-loss coverage in the 2026 plan year. Kentucky Medicaid does not.

This is a jurisdiction inversion: the state employee plan covers what the Medicaid program excludes. The verbatim KEHP 2026 Benefits Selection Guide on GLP-1 weight-loss drug benefit changes:

“Change in GLP-1 Weight Loss Drug Benefit

LivingWell CDHP
  • Old: Deductible, then 20%
  • New: Deductible, then 25%

LivingWell PPO
  • Old: $40 Co-pay
  • New: Deductible, then 25%

LivingWell Basic CDHP
  • No changes

LivingWell HDHP
  • No changes”

The benefits grid verbatim:

“GLP-1 Weight Loss Drugs
LivingWell CDHP: In-Network — Deductible, then 25% / Out-of-Network — Deductible, then 50%
LivingWell PPO: In-Network — Deductible, then 25% / Out-of-Network — Deductible, then 50%
LivingWell Basic CDHP: In-Network — Deductible, then 30% / Out-of-Network — Deductible, then 50%
LivingWell HDHP: In-Network — Deductible, then 30% / Out-of-Network — Deductible, then 50%”

KEHP is governed by a different statutory framework (KRS Chapter 18A and related Personnel Cabinet authority), funded through state employer and employee contributions rather than Title XIX Medicaid federal matching, and serves a different population (state employees and their dependents rather than low-income Medicaid beneficiaries). The 907 KAR 23:010 Section 5(2)(a) exclusion that governs Medicaid pharmacy benefits does not apply to KEHP. The two programs are separate and distinct; KEHP’s continued GLP-1 weight-loss coverage does not override, waive, or affect the Medicaid categorical exclusion.

Compare to Indiana (Pattern #16): Indiana presents the opposite inversion. The Indiana Medicaid program excludes GLP-1s for adult weight management under 405 IAC 5-24-3(b)(1). The Indiana State Personnel Department employee health plan (administered by CVS Caremark)also dropped GLP-1 weight-loss coverage effective January 1, 2026. Indiana’s state-employee plan moved toward exclusion; Kentucky’s state-employee plan retained coverage (at increased cost-sharing). KY Medicaid excludes + KEHP covers. IN Medicaid excludes + state employee plan dropped. These are structurally opposite-of-opposite outcomes in the same 2025–2026 policy cycle.

MedImpact Healthcare Systems, Inc.: the statewide PBM (replaced Magellan January 1, 2024)

Pharmacy benefits for Kentucky Medicaid — across all five MCOs and the FFS population — are administered by MedImpact Healthcare Systems, Inc., which assumed the role from Magellan Medicaid Administration effective January 1, 2024.

Older Kentucky Medicaid PDL documents (pre-2024) reference Magellan Medicaid Administration as the PBM. Magellan Rx Management was acquired by Prime Therapeutics in 2022 (transaction closed late 2022) — but Prime Therapeutics is NOT the Kentucky Medicaid PBM. The current operational PBM is MedImpact. Any reference to Magellan or Prime Therapeutics as the current Kentucky Medicaid PBM is outdated.

The transition is confirmed across multiple MCO-level primary sources. Humana Healthy Horizons verbatim:

“MedImpact administers pharmacy benefits for all Medicaid members in Kentucky, including Humana Healthy Horizons in Kentucky members. The PBM for Humana Healthy Horizons in Kentucky is MedImpact, which processes all pharmacy claims and provides pharmacy-related services with input from the Kentucky Department for Medicaid Services. As a Humana Healthy Horizons in Kentucky enrollee, pharmacy coverage includes access to many safe and effective medicines that are part of a formulary, also known as the Kentucky Medicaid Single Preferred Drug List (PDL).”

Passport Health Plan by Molina verbatim:

“Starting on July 1, 2021, Passport began working with a pharmacy benefits manager (PBM), MedImpact Healthcare Systems, Inc., that serves all members in managed care. MedImpact administers pharmacy benefits for Kentucky Medicaid Members.”

MedImpact operates the Kentucky Medicaid Single PDL through the MedImpact Kentucky portal at kyportal.medimpact.com. The PDL and all PA criteria documents are posted there and are updated on the DMS Pharmacy & Therapeutics Advisory Committee (P&T AC) approval cycle. MedImpact took over managed care PBM administration in July 2021 and FFS PBM administration on January 1, 2024, making the statewide carve-out structure uniform across both delivery systems.

This architecture is structurally identical to Indiana’s Pattern #16 (OptumRx-administered Statewide Uniform Preferred Drug List): a single contracted PBM administers a uniform statewide formulary applied equally to all five MCOs and the FFS population, with no MCO-level deviation permitted for GLP-1 medications.

Five-MCO carve-out structure: uniform statewide formulary

Kentucky Medicaid contracts with five MCOs for most beneficiaries:

• Aetna Better Health of Kentucky
• Anthem Blue Cross and Blue Shield Medicaid (HealthKeepers)
• Humana Healthy Horizons in Kentucky
• Passport Health Plan by Molina Healthcare
• WellCare of Kentucky (operating as Wellpoint Kentucky in some 2025–2026 materials; WellCare branding remains active for Medicaid)

All five MCOs defer pharmacy benefits to the MedImpact-administered Kentucky Medicaid Single PDL. There is no MCO-level deviation in pharmacy formulary administration for GLP-1 medications. WellCare of Kentucky states verbatim: the PDL “is a clinical guide of prescription drug products selected by the Department for Medicaid Services’ Pharmaceutical and Therapeutics (P&T) Committee based on a drug’s efficacy, safety, side effects, pharmacokinetics, clinical literature and cost-effectiveness,” directing users to the MedImpact Kentucky portal.

Practical implication: A Kentucky Medicaid enrollee’s GLP-1 coverage status is determined by the statewide MedImpact PDL and PA criteria — not by their assigned MCO. Switching MCOs within Kentucky Medicaid does not change GLP-1 coverage access. Both the categorical exclusion for weight management and the carve-outs for MACE, MASH, and OSA apply uniformly regardless of MCO assignment.

GLP-1 coverage for type 2 diabetes vs. weight loss: the critical distinction

Kentucky Medicaid covers GLP-1 receptor agonists for type 2 diabetes. It does not cover them for chronic weight management. These are two distinct clinical pathways administered under separate parts of the MedImpact PA criteria document.

The footnote in the GLP-1 RA T2D PA criteria is the single most-citable operational confirmation: “*Drugs used for anorexia, weight loss, or weight gain are excluded from coverage.” This language appears at the bottom of the T2D class criteria, establishing that even within the GLP-1 RA context, weight-management use is categorically excluded.

Kentucky in the 21-state series: structural comparison

Kentucky’s architecture can be mapped to five prior states for structural comparisons readers may find most useful:

• vs. Texas (Pattern #1): TX uses 1 TAC § 354.1832 + Acentra PDL omission with no non-weight-loss carve-outs. KY uses 907 KAR 23:010 Section 5(2)(a) + MedImpact PDL but has FDA-label-specific Wegovy and Zepbound carve-outs TX lacks. Both have explicit regulatory exclusions administered by a single statewide PBM.
• vs. Ohio (Pattern #6): OH added a dedicated “Metabolic Modifiers” PDL class January 7, 2026 to operationalize Wegovy non-weight-loss carve-outs (MACE + MASH). KY administers the same FDA-label carve-outs through stand-alone PA criteria documents without a named PDL class. OH’s structure is more transparent; KY’s is more fragmented but functionally similar.
• vs. New York (Pattern #3): NY’s Wegovy MACE pathway is gated on BMI ≥ 40 with a two-attempt lifetime limit. KY’s MACE pathway uses BMI ≥ 27 (FDA-label minimum) with no lifetime-attempts cap. KY’s Wegovy MACE is the most permissive MACE threshold in the series.
• vs. Indiana (Pattern #16): Both states use a single-PBM carve-out architecture. Both have failed coverage-expansion attempts in the 2025–2026 cycle: Indiana’s HB 1202 (Shackleford) died in committee; Kentucky’s proposed 907 KAR 23:010 amendment advanced through agency approval and public hearing before being extinguished by SB 65. Kentucky’s attempt advanced further procedurally. Indiana lists Zepbound as Preferred (for T2D); KY does not list Zepbound on the PDL table at all.
• vs. California (Pattern #2): CA reversed course (eliminated then partially restored Wegovy MASH-only in March 2026). KY has continuously covered Wegovy MASH (never eliminated). KY also has a Wegovy MACE pathway that CA lacks. KY’s Wegovy coverage profile is therefore broader for non-weight-loss indications than CA’s, while remaining categorically exclusionary for weight management.

Excluded populations and what the exclusion means practically

Kentucky adults on Medicaid who have obesity as a primary diagnosis — without T2D, established cardiovascular disease, MASH, or moderate-to-severe OSA — have no Kentucky Medicaid pathway for Wegovy, Zepbound, or any other GLP-1 for chronic weight management. The DMS regulatory filing estimated approximately 350,000 Kentucky Medicaid members carry an obesity-related diagnosis, representing roughly 22% of the 1.6 million total enrollment.

Additional populations affected by the T2D exclusion from carve-out pathways:

• Patients with T2D plus established cardiovascular disease who would clinically qualify for Wegovy under the FDA SELECT label — they are routed to the T2D GLP-1 RA class (Ozempic, Trulicity, Victoza) rather than the Wegovy MACE carve-out.
• Patients with T2D plus MASH who would clinically qualify for Wegovy’s MASH indication — they are routed to Ozempic’s MASH/MASLD pathway in the T2D class, not the Wegovy MASH carve-out.
• Patients with T2D plus moderate-to-severe OSA who would clinically qualify for Zepbound under the FDA OSA label — they are routed to the T2D GLP-1 RA class, not the Zepbound OSA carve-out.

Note on EPSDT (pediatric coverage): No Kentucky-specific GLP-1 EPSDT bulletin has been identified in the primary sources verified for this article. Indiana has published IHCP Bulletin BT2023148 authorizing Wegovy and Saxenda for EPSDT-eligible members under age 21 with morbid obesity. No Kentucky equivalent has been located. The article writer makes no assumption about Kentucky EPSDT coverage of GLP-1 weight-loss drugs without a verified primary-source citation.

Patient action steps and the appeal pathway

For Kentucky Medicaid members seeking GLP-1 coverage, the operative question is which pathway applies to their clinical situation:

1. T2D diagnosis: Ask your prescriber about Ozempic, Trulicity, or Victoza (Preferred under the GLP-1 RA T2D class; PA required with A1c ≥ 6.5 + ICD-10 T2DM documentation). Mounjaro and Rybelsus are Non-Preferred (step-therapy required).
2. Established cardiovascular disease, no T2D, BMI ≥ 27, age ≥ 45: Ask your prescriber about the Wegovy MACE PA pathway. Prior MI, prior stroke (ischemic or hemorrhagic), or symptomatic PAD (ABI < 0.85 at rest) qualifies as established CV disease. Lipid-lowering and adjunctive cardiovascular therapy optimization documentation is required.
3. MASH (F2–F3 fibrosis), no T2D, age ≥ 18:Ask your gastroenterologist or hepatologist about the Wegovy MASH PA pathway. Liver biopsy or FIB-4 > 2.67 documentation is required. Wegovy injectable only (not Wegovy tablet).
4. Moderate-to-severe OSA, no diabetes, BMI ≥ 30:Ask your sleep specialist or neurologist about the Zepbound OSA PA pathway. AHI/RDI/REI ≥ 15 (or ≥ 5 with symptoms) confirmed by sleep study is required, plus documentation of a 3-month trial-and-failure of CPAP/BiPAP/APAP (unless contraindicated or intolerable).
5. Obesity only, no qualifying comorbidity: Kentucky Medicaid does not cover GLP-1s for chronic weight management. The SB 65 moratorium prohibits DMS from re-promulgating a substantially-similar coverage-expansion regulation until June 1, 2027. Cash-pay compounded semaglutide or tirzepatide from a licensed pharmacy or telehealth provider is the primary access route. See the GLP-1 pricing index for current market pricing.

Appeal pathway for coverage denials

For denials of the MACE, MASH, or OSA carve-out pathways (not denials of the categorical weight-management exclusion, which is a policy exclusion not subject to successful adjudication-error appeal):

• MCO internal appeal: File within approximately 60 days of the adverse benefit determination notice (deadline varies by MCO; verify with your assigned MCO). Internal appeal exhaustion is typically required before State Fair Hearing.
• State Fair Hearing request: File within 120 days from the date of the final appeal decision letter, per the cross-MCO administrative regulation framework at 907 KAR 1:560. Mail written request to: Kentucky Department for Medicaid Services, Division of Program Quality and Outcomes, Attention: State Fair Hearings, 275 East Main Street, 6C-C, Frankfort, KY 40621-0001.
• Hearing scope: A fair hearing can overturn an adjudication-error denial (incorrect application of the PA criteria to your clinical facts). It cannot override the policy-level categorical exclusion under 907 KAR 23:010 Section 5(2)(a) for weight management — that is a regulatory-policy question, not an adjudication question. For denials of the weight-management indication specifically, the hearing will not produce a different outcome absent a change in the underlying regulation.
• Legal aid: Kentucky Equal Justice Center provides free Medicaid appeals assistance for qualifying individuals.

Related research

• Tennessee Medicaid GLP-1 coverage (2026): Pattern #13 — positive-coverage expansion via Sequence 10-34-25 — The cleanest counter-example to Kentucky in the 21-state series. TN and KY used identical procedural posture (executive-branch administrative rulemaking); TN’s General Assembly chose NOT to nullify TennCare’s obesity-coverage expansion; KY’s General Assembly chose to nullify DMS’s expansion via SB 65 override April 14, 2026. Same procedure, opposite outcomes.
• Indiana Medicaid (IHCP) GLP-1 coverage (2026): Pattern #16 — regulatory exclusion + Zepbound-preferred anomaly — The KEHP-Medicaid jurisdiction inversion comparison. Indiana Medicaid excludes GLP-1s for adult weight management (405 IAC 5-24-3(b)(1)) AND the Indiana state employee plan dropped GLP-1 weight-loss coverage January 1, 2026. Kentucky Medicaid excludes GLP-1s for weight management AND the KEHP state employee plan retains coverage (at 25% coinsurance). Opposite-of-opposite outcomes in the same 2025–2026 cycle.
• GLP-1 pricing index: compounded semaglutide and tirzepatide market rates across 100+ providers — Kentucky is a confirmed nullified-amendment exclusion state with approximately 350,000 Medicaid members carrying an obesity diagnosis and no Medicaid weight-management pathway through at least June 1, 2027. That population — excluded from Medicaid and without employer coverage equivalent to KEHP — is the core cash-pay compounded GLP-1 demand pool. The pricing index tracks current market rates across the full provider range for patients evaluating compounded semaglutide or tirzepatide.
• State Medicaid GLP-1 coverage hub — all 21 verified states — the 50-state coverage tracker. Kentucky is Pattern #21 (Nullified-amendment exclusion state). The hub documents the full taxonomy across positive-coverage states (TN, WI, MN, NC), conditional coverage states (VA), indication-anchored states (WA, OH, CA, MI, MD), and explicit non-coverage states (TX, IL, NJ, NY, AZ, PA, MA, IN, KY).
• GLP-1 insurance coverage dropped: appeal playbook — structured process for appealing GLP-1 coverage denials, applicable to Kentucky Medicaid MACE/MASH/OSA carve-out denials where the denial may be an adjudication error (incorrect application of PA criteria to clinical facts) rather than a policy-level exclusion.
• Washington Medicaid GLP-1 coverage (2026): indication-anchored (MACE, MASH, OSA only — not weight loss) — WA and KY share the same indication-anchored architecture for Wegovy and Zepbound (non-weight-loss FDA indications only). WA’s PA criteria use the verbatim phrase “is not covered by Apple Health for weight loss.” KY’s exclusion is anchored in regulatory text (907 KAR 23:010 Section 5(2)(a)) with the carve-outs in stand-alone PA criteria documents. The KY structure is more fragmented than WA’s policy-bulletin approach.
• Alabama Medicaid GLP-1 coverage (2026): Pattern #23 — in-PDL OSA-only Zepbound footnote + off-PDL Cardiac Agents Wegovy MACE pathway — Alabama and Kentucky both have OSA-only Zepbound and MACE-only Wegovy carve-outs, reaching the same de-facto exclusion outcome via different operational mechanisms. Alabama’s Zepbound OSA carve-out is enumerated in the PDL drug class table via footnote ^ (“Zepbound is non-covered for weight reduction without OSA”) — Kentucky’s is in stand-alone PA criteria PDFs on the MedImpact portal. Alabama does NOT require a 3-month CPAP trial-and-failure or sleep specialist consultation (both required in Kentucky). Alabama’s PBM is Acentra Health (not MedImpact); its Wegovy MACE pathway is in the PA Form 369 Cardiac Agents section (not a stand-alone PA PDF).

Last verified: May 10, 2026 — 907 KAR 23:010 (LRC, verified direct), MedImpact Kentucky Medicaid PDL (May 2026), Wegovy PA Criteria (effective January 3, 2026), Zepbound PA Criteria (effective July 1, 2025), Kentucky Medicaid PA Criteria GLP-1 RA T2D class (MedImpact portal), SB 65 (2026 RS, direct PDF, footer confirms April 14, 2026), Proposed 907 KAR 23:010 amendment (LRC filing, direct PDF), KEHP 2026 Benefits Selection Guide (Personnel Cabinet, direct PDF), CMS TEAMKY 1115 demonstration (medicaid.gov), Humana + Passport + WellCare KY MCO deferral statements (direct web verification). MedImpact PDL and PA criteria are updated on the DMS P&T AC approval cycle; verify current documents at kyportal.medimpact.com before making any coverage determination.